ArticleBritish journal of cancer2005
Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 72 citations in OpenAlex.
- Profiles of FGF2, HGF, Fas/CD95, CASP9, ALDH1A1, and GLUT1 in GEP-NETs: A Comparative Tumor-Margin Study Based on Protein Concentration.International journal of molecular sciences · 2026Article
- FASLG Derived from Fibroblasts in Hydroxyapatite-Rich Microenvironment Induces Urothelial Anoikis to Trigger Randall's Plaque Exposure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Association of Death Receptors and TGF-β1 Expression in Urothelial Bladder Cancer and Their Prognostic Significance.Biomedicines · 2024Article
- Review
- High FAS expression correlates with a better prognosis and efficacy of taxanes and target regents in breast cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- In silico analysis of the prognostic value of FAS mRNA in malignancies.Journal of Cancer · 2020Article
- Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.Environmental toxicology · 2019Article
- High expression of active ATF6 aggravates endoplasmic reticulum stress‑induced vascular endothelial cell apoptosis through the mitochondrial apoptotic pathway.Molecular medicine reports · 2018Article
- Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.Cell death & disease · 2018Review
- DcR3 induces proliferation, migration, invasion, and EMT in gastric cancer cells via the PI3K/AKT/GSK-3β/β-catenin signaling pathway.OncoTargets and therapy · 2018Article
- Review
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- Role of lifeguard β-isoform in the development of breast cancer.Oncology reports · 2014Article
- Improved production of recombinant human Fas ligand extracellular domain in Pichia pastoris: yield enhancement using disposable culture-bag and its application to site-specific chemical modifications.BMC biotechnology · 2014Article
- Amplification of Genomic DNA for Decoy Receptor 3 Predicts Post-Resection Disease Recurrence in Breast Cancer Patients.World journal of oncology · 2014Article
- Prognostic value of the Fas/Fas ligand system in breast cancer.Contemporary oncology (Poznan, Poland) · 2013Article
- MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival.International journal of clinical and experimental medicine · 2013Article
- Bladder cancer: a simple model becomes complex.Current genomics · 2012Article
- Prognostic impact of apoptosis marker Fas (CD95) and its ligand (FasL) on bladder cancer in Egypt: study of the effect of schistosomiasis.Ecancermedicalscience · 2012Article
- Pro- and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy.TheScientificWorldJournal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The death receptor Fas (Apo1/CD95) and Fas ligand (FasL) system is recognised as a major pathway for the induction of apoptosis in vivo, and antiapoptosis via its blockade plays a critical role in carcinogenesis and progression in several malignancies. However, the function of Fas-FasL system in urothelial cancer (UC) has not been elucidated. We therefore investigated the expression of Fas, FasL and Decoy receptor 3 for FasL (DcR3) in UC specimens and cell lines, and examined the cytotoxic effect of an anti-Fas-activating monoclonal antibody (mAb) in vitro. Immunohistochemical examinations of Fas-related molecules were performed on 123 UC and 30 normal urothelium surgical specimens. Normal urothelium showed Fas staining in the cell membrane and cytoplasm. In UC, less frequent Fas expression was significantly associated with a higher pathological grade (P < 0.0001), a more advanced stage (P = 0.023) and poorer prognosis (P = 0.010). Fas and the absence thereof were suggested to be crucial factors with which to select patients requiring more aggressive treatment. Moreover, low-dose anti-Fas-activating mAb sensitised resistant cells to adriamycin, and this synergistic effect could be applied in the development of new treatment strategy for UC patients with multidrug-resistant tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.